RS62946B1 - Kristalni oblici - Google Patents
Kristalni obliciInfo
- Publication number
- RS62946B1 RS62946B1 RS20220163A RSP20220163A RS62946B1 RS 62946 B1 RS62946 B1 RS 62946B1 RS 20220163 A RS20220163 A RS 20220163A RS P20220163 A RSP20220163 A RS P20220163A RS 62946 B1 RS62946 B1 RS 62946B1
- Authority
- RS
- Serbia
- Prior art keywords
- crystalline form
- piperazine
- amino
- carbonyl
- carboxylic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016072562 | 2016-09-22 | ||
| PCT/EP2017/073858 WO2018055016A1 (en) | 2016-09-22 | 2017-09-21 | Crystalline forms |
| EP17771436.7A EP3515924B1 (en) | 2016-09-22 | 2017-09-21 | Crystalline forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62946B1 true RS62946B1 (sr) | 2022-03-31 |
Family
ID=59923448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220163A RS62946B1 (sr) | 2016-09-22 | 2017-09-21 | Kristalni oblici |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10730896B2 (enExample) |
| EP (2) | EP3981774A1 (enExample) |
| JP (1) | JP7097369B2 (enExample) |
| KR (1) | KR102552795B1 (enExample) |
| CN (1) | CN109715639B (enExample) |
| AU (1) | AU2017331930B2 (enExample) |
| CA (1) | CA3037794A1 (enExample) |
| CL (1) | CL2019000728A1 (enExample) |
| CY (1) | CY1125052T1 (enExample) |
| DK (1) | DK3515924T3 (enExample) |
| EA (1) | EA201990723A1 (enExample) |
| ES (1) | ES2908572T3 (enExample) |
| HR (1) | HRP20220234T1 (enExample) |
| HU (1) | HUE057772T2 (enExample) |
| IL (1) | IL265445B2 (enExample) |
| LT (1) | LT3515924T (enExample) |
| MA (1) | MA46266B1 (enExample) |
| MX (1) | MX381590B (enExample) |
| MY (1) | MY193080A (enExample) |
| PH (1) | PH12019500567B1 (enExample) |
| PL (1) | PL3515924T3 (enExample) |
| PT (1) | PT3515924T (enExample) |
| RS (1) | RS62946B1 (enExample) |
| SI (1) | SI3515924T1 (enExample) |
| TW (1) | TWI752086B (enExample) |
| UA (1) | UA124073C2 (enExample) |
| WO (1) | WO2018055016A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA124073C2 (uk) | 2016-09-22 | 2021-07-14 | Ідорсія Фармасьютікалз Лтд | Кристалічні форми гідрохлориду складного бутилового ефіру 4-((r)-2-{[6-((s)-3-метоксипіролідин-1-іл)-2-фенілпіримідин-4-карбоніл]-аміно}-3-фосфонопропіоніл)-піперазин-1-карбонової кислоти |
| MY205605A (en) | 2017-03-15 | 2024-10-29 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
| MX2023000601A (es) | 2020-07-15 | 2023-02-13 | Idorsia Pharmaceuticals Ltd | Composicion farmaceutica acuosa que comprende un antagonista del receptor p2y12. |
| MX2024000653A (es) | 2021-07-13 | 2024-01-31 | Idorsia Pharmaceuticals Ltd | Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| CA2375920A1 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| CN1747732A (zh) | 2002-12-11 | 2006-03-15 | 舍林股份公司 | 作为血小板腺苷二磷酸受体拮抗剂的2－氨基羰基喹啉化合物 |
| PL1611144T3 (pl) | 2003-04-09 | 2011-03-31 | Wyeth Llc | Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA) |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| EP1940814B1 (en) | 2005-10-21 | 2013-05-22 | Actelion Pharmaceuticals Ltd. | Piperazine derivatives as antimalarial agents |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| CL2007003038A1 (es) | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| CA2684644A1 (en) | 2007-04-23 | 2008-10-30 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| AR069494A1 (es) | 2007-11-29 | 2010-01-27 | Actelion Pharmaceuticals Ltd | Derivados de acidos fosfonicos |
| WO2009080226A2 (en) | 2007-12-26 | 2009-07-02 | Sanofis-Aventis | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| WO2009080227A2 (en) | 2007-12-26 | 2009-07-02 | Sanofi-Aventis | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| AU2010233378A1 (en) | 2009-04-08 | 2011-11-24 | Actelion Pharmaceuticals Ltd. | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as ADP receptor antagonists |
| BRPI1015145A2 (pt) | 2009-04-22 | 2018-01-30 | Actelion Pharmaceuticals Ltd | derivados de tiazol e seu uso como receptores antagonistas de p2y12 |
| UA124073C2 (uk) | 2016-09-22 | 2021-07-14 | Ідорсія Фармасьютікалз Лтд | Кристалічні форми гідрохлориду складного бутилового ефіру 4-((r)-2-{[6-((s)-3-метоксипіролідин-1-іл)-2-фенілпіримідин-4-карбоніл]-аміно}-3-фосфонопропіоніл)-піперазин-1-карбонової кислоти |
| MY205605A (en) | 2017-03-15 | 2024-10-29 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
| MX2023000601A (es) | 2020-07-15 | 2023-02-13 | Idorsia Pharmaceuticals Ltd | Composicion farmaceutica acuosa que comprende un antagonista del receptor p2y12. |
-
2017
- 2017-09-21 UA UAA201903751A patent/UA124073C2/uk unknown
- 2017-09-21 MX MX2019003093A patent/MX381590B/es unknown
- 2017-09-21 MA MA46266A patent/MA46266B1/fr unknown
- 2017-09-21 MY MYPI2019001474A patent/MY193080A/en unknown
- 2017-09-21 HR HRP20220234TT patent/HRP20220234T1/hr unknown
- 2017-09-21 EP EP21206477.8A patent/EP3981774A1/en not_active Withdrawn
- 2017-09-21 CA CA3037794A patent/CA3037794A1/en active Pending
- 2017-09-21 IL IL265445A patent/IL265445B2/en unknown
- 2017-09-21 WO PCT/EP2017/073858 patent/WO2018055016A1/en not_active Ceased
- 2017-09-21 DK DK17771436.7T patent/DK3515924T3/da active
- 2017-09-21 ES ES17771436T patent/ES2908572T3/es active Active
- 2017-09-21 JP JP2019536696A patent/JP7097369B2/ja active Active
- 2017-09-21 HU HUE17771436A patent/HUE057772T2/hu unknown
- 2017-09-21 TW TW106132387A patent/TWI752086B/zh active
- 2017-09-21 PL PL17771436T patent/PL3515924T3/pl unknown
- 2017-09-21 US US16/335,973 patent/US10730896B2/en active Active
- 2017-09-21 PT PT177714367T patent/PT3515924T/pt unknown
- 2017-09-21 EA EA201990723A patent/EA201990723A1/ru unknown
- 2017-09-21 LT LTEPPCT/EP2017/073858T patent/LT3515924T/lt unknown
- 2017-09-21 PH PH1/2019/500567A patent/PH12019500567B1/en unknown
- 2017-09-21 AU AU2017331930A patent/AU2017331930B2/en active Active
- 2017-09-21 KR KR1020197011330A patent/KR102552795B1/ko active Active
- 2017-09-21 EP EP17771436.7A patent/EP3515924B1/en active Active
- 2017-09-21 CN CN201780057793.2A patent/CN109715639B/zh active Active
- 2017-09-21 SI SI201731102T patent/SI3515924T1/sl unknown
- 2017-09-21 RS RS20220163A patent/RS62946B1/sr unknown
-
2019
- 2019-03-21 CL CL2019000728A patent/CL2019000728A1/es unknown
-
2020
- 2020-07-24 US US16/938,730 patent/US11365209B2/en active Active
-
2022
- 2022-03-09 CY CY20221100195T patent/CY1125052T1/el unknown
- 2022-05-10 US US17/741,427 patent/US12227532B2/en active Active
-
2025
- 2025-01-17 US US19/028,423 patent/US20250163086A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12227532B2 (en) | Crystalline forms | |
| JP6078601B2 (ja) | Ｍｇａｔ２阻害剤としてのアリールジヒドロピリジノンおよびピペリジノン | |
| EP3004059B1 (en) | Dihydropyridinone mgat2 inhibitors | |
| JP2020525475A (ja) | Ｎ−［１−（５−シアノ−ピリジン−２−イルメチル）−１ｈ−ピラゾール−３−イル］−２−［４−（１−トリフルオロメチル−シクロプロピル）−フェニル］−アセタミドの結晶形 | |
| JP7142406B2 (ja) | インドリジン誘導体及びその医学的応用 | |
| JPH04257579A (ja) | ４−（２−フェニルエチル）ピペリジン−１−イル基をもつエタノールおよびエタノン誘導体、その製造および治療的応用 | |
| HK40009744B (en) | Crystalline forms | |
| NZ750772B2 (en) | Crystalline forms | |
| JP2008531613A (ja) | Ｃｐｔを阻害するアミノブタン酸誘導体 | |
| BR112019004845B1 (pt) | Forma cristalina de cloridrato de éster butílico de ácido 4-((r)-2-{[6-((s) -3-metoxi-pirrolidin-1-il)-2-fenilpirimidina-4 carbonil]-amino}-3-fosfono-propionil)- piperazina-1-carboxílico, usos da mesma e de éster butílico de ácido 4-((r)-2-{[6- ((s)-3-metoxi-pirrolidin-1-il)-2- fenil-pirimidina-4-carbonil]-amino}-3- fosfonopropionil)-piperazina-1-carboxílico, ou um sal farmaceuticamente aceitável do mesmo, processos para preparação da mesma, e, composição farmacêutica | |
| AU2018257332B2 (en) | Heterocyclic compound | |
| HK40014590A (en) | Heterocyclic compound | |
| HK1197231B (en) | Aryl dihydropyridinones and piperidinones as mgat2 inhibitors |